24 May 2013
Keywords: Tranzyme, Options, Sale or merger; Ache, Brazil, Bidding interest
Article | 11 February 2013
Following two recent R&D pipeline disappointments, the board of directors of US biotech firm Tranzyme (Nasdaq: TZYM) has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 February 2013
23 May 2013
© 2013 thepharmaletter.com